Skip to Main Content

Paper Details

Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial.
Breast
8
2022
Author NameAffiliation
Fatima CardosoChampalimaud Clinical Centre, Champalimaud Foundation
  • 1 - 1

Datasets

Release 1.2